BD declares $1.05 quarterly dividend, sets Sept 30 payment date
BD (Becton, Dickinson and Company) declared a $1.05 quarterly dividend, payable September 30, 2026, to shareholders of record on September 9, 2026. The move keeps the annualized dividend rate steady at $4.20 per share.

*this image is generated using AI for illustrative purposes only.
The Board of Directors of BD (Becton, Dickinson and Company) has declared a quarterly dividend of $1.05 per common share, signaling continued commitment to shareholder returns. The dividend is payable on September 30, 2026, to holders of record as of September 9, 2026. This announcement ensures that eligible shareholders will receive their distribution on the specified date, maintaining the company's indicated annual dividend rate of $4.20 per share.
Dividend Details
The key dates and figures for this dividend distribution are outlined below:
| Metric | Detail |
|---|---|
| Quarterly Dividend | $1.05 per share |
| Record Date | September 9, 2026 |
| Payment Date | September 30, 2026 |
| Annualized Rate | $4.20 per share |
Shareholders must hold BD common stock by the close of business on the record date to be eligible for the payment. The company did not disclose any changes to its broader capital allocation strategy alongside this routine quarterly declaration.
About BD
BD is a leading global medical technology company focused on advancing health through innovation in medical essentials, connected care, biopharma systems, and interventional solutions. With more than 60,000 employees worldwide, the company delivers billions of products annually aimed at optimizing clinical operations and improving patient care outcomes.
How might BD's consistent dividend payout impact its ability to fund R&D initiatives in connected care and biopharma systems?
What does the maintenance of the $4.20 annualized dividend rate suggest about BD's confidence in its near-term cash flow generation?
Could this steady shareholder return strategy influence BD's valuation relative to peers who are prioritizing aggressive M&A activity?


























